As previously outlined, it is most beneficial if NSCLC patients are treated with inhibitors that have broad activity against resistance mutations, are compact with intrinsically good brain penetration characteristics and are not very good ABCB1/ABCG2 substrates. Here, ABCG2 is linked to non-small cell lung carcinoma.